FOXP3 and neoplasm: The results showed that pretreatment with azacitidine followed by sequential combination with immunotherapeutic agents only significantly reduced the density of FoxP3+ regulatory T cells in the tumor microenvironment, without effectively enhancing the infiltration of effector T cells (CD8+ T cells).